Mono Pharmacare Peer Comparison

₹9.00

₹0.00 (0.00%)

As on 31-Aug-2026IST

Market cap

₹16 Cr

Revenue (TTM)

₹168 Cr

P/E Ratio

45

P/B Ratio

0.5

Div. Yield

0 %

Edit

	Mono Pharmacare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	16	30,606	30,088	28,551	25,816
Revenue (₹ Cr)	168	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	3.11	414.00	288.22	-371.81	387.35
Net Margin (%)	1.83	11.23	14.79	-3.93	26.01
RoE (%)	10.47	8.38	29.77	-3.85	25.18
Price to Earnings	45.05	74.83	104.39	--	66.84
Price-To-Book	0.51	6.08	22.41	3.57	14.93

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Mono Pharmacare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	168.34	3,012.00	1,284.27	9,151.18	1,006.88
Total Income	169.32	3,074.00	1,296.22	9,312.95	1,023.80
Total Expenditure	160.71	2,619.00	1,028.33	7,733.31	774.80
EBITDA	7.64	393.00	255.95	1,417.87	232.07
Depreciation	0.13	217.00	36.59	816.34	26.62
EBIT	7.51	176.00	219.36	601.53	205.45
Interest	4.03	254.00	36.78	421.59	6.22
Other Income	0.98	62.00	11.95	161.77	16.93
Exceptional Items	--	--	--	--	--
Profit before Tax	4.46	-16.00	194.52	414.64	216.16
Provision for Tax	1.36	41.00	60.16	323.51	55.75
Profit after Tax	3.11	-57.00	134.36	91.13	160.42

Liabilities (₹ Cr)

	Mono Pharmacare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	31.20	4,353.00	540.98	8,125.47	1,309.63
Minority Interest	0.04	304.00	0.00	--	10.45
Non-Current Liabilities	26.00	887.00	122.65	3,392.72	26.93
Current Liabilities	52.78	2,042.00	786.03	3,850.56	202.25
Total Liabilities	110.05	8,100.00	1,451.43	15,513.53	1,549.26

Assets (₹ Cr)

	Mono Pharmacare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	1.02	5,017.00	386.29	9,487.47	757.63
Current Assets	108.99	2,465.00	1,063.37	5,881.28	791.64
Total Assets	110.05	8,100.00	1,451.43	15,513.53	1,549.26
Total Debt*	53.56	1,859.00	393.17	4,720.27	8.18
Net Current Assets	56.21	423.00	277.34	2,030.72	589.39
Contingent Liabilities	--	770.26	12.25	99.76	15.38

Cashflow (₹ Cr)

	Mono Pharmacare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-4.30	-22.00	159.18	892.30	118.34
Cash Flow from Investing Activities	-0.23	-783.00	-64.81	-477.46	-223.94
Cash from Financing Activities	4.86	409.00	-39.81	-440.83	261.12
Net Cash Inflow / Outflow	0.33	-396.00	54.56	-25.99	155.52

Ratios

Profitability Ratios

	Mono Pharmacare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	11.00	4.07	26.97	6.61	20.14
ROE (%)	10.47	-1.48	30.68	1.14	16.19
ROA (%)	3.25	-0.78	10.50	0.60	12.13
EBIT Margin (%)	5.12	15.11	20.86	17.26	24.73
Net Margin (%)	1.83	-1.85	10.37	0.98	15.67
Cash Profit Margin (%)	1.92	4.14	7.13	8.54	18.58

Growth Ratios

	Mono Pharmacare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	37.60	7.65	50.40	11.99	40.34
EBIT Growth (%)	34.14	272.95	54.77	15.16	83.12
Net Profit Growth (%)	26.32	87.92	47.63	411.39	229.35
EPS Growth (%)	26.53	90.35	45.69	410.84	67.16
Book Value Growth (%)	10.99	29.77	42.49	2.28	94.96

Valuation Ratios

	Mono Pharmacare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	13.21	0.00	0.00	326.26	62.97
Price / Book Value	1.31	5.31	0.00	3.69	15.26
Dividend Yield (%)	0.00	0.00	--	0.06	0.06
EV/EBITDA	10.87	54.36	1.09	21.49	79.31
Market Cap (₹ Cr)	40.81	23,064.69	0.00	29,731.27	19,988.69

Solvency Ratios

	Mono Pharmacare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	1.72	0.43	0.76	0.59	0.01
Short term debt to equity ratio	0.88	0.11	0.54	0.12	0.01
Current Ratio	2.07	1.21	1.35	1.53	3.91
Quick Ratio	1.02	0.85	0.69	0.93	3.02
Interest Coverage	2.11	0.94	6.29	1.98	35.76

Operating Efficiency Ratios

	Mono Pharmacare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	24.88	21.95	25.21	25.67	28.85
Asset Turnover	1.76	0.53	1.87	0.70	0.76
Receivable days	79.66	60.36	47.59	77.05	90.06
Inventory Days	105.89	64.42	62.58	77.13	61.02
Payable days	34.13	218.94	228.78	173.49	96.06
Cash Conversion Cycle	151.42	-94.15	-118.62	-19.30	55.02